耗材描述
Parsatuzumab
产品活性:Parsatuzumab (Anti-EGFL7; RG 7414) 是一种人源化单克隆抗体,作为免疫调节剂与 EGFL7 结合。Parsatuzumab 选择性阻断 EGFL7 与内皮细胞之间的相互作用,可能抑制血管再生,降低血管内皮生长因子 (VEGF) 抑制。
产品来源: https://www.medchemexpress.cn/parsatuzumab.html
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:VEGFR
In Vitro: EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival.
Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells.
In Vivo: Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models.
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL.
相关产品:Sorafenib | Lenvatinib | Bevacizumab | Regorafenib | Sunitinib | Nintedanib | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | Glycine | PD173074 | Tanshinone IIA | Fruquintinib | 5Z-7-Oxozeaenol | Vandetanib | SU 5402 | Linifanib | Foretinib | SPHINX31 | Ripretinib | GW806742X | Dovitinib
品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物;10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;设有专业的实验中心和严格的质控、验证体系;提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;产品的生物活性多经各国客户实验验证;Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;与世界各大制药公司及知名科研机构建立了长期的合作。